NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and…Original Article
Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
